New drug combo aims for deep remission in rare blood cancer
NCT ID NCT07259122
Summary
This study is testing a combination of three drugs (zanubrutinib, bendamustine, and a CD20 antibody) for people newly diagnosed with a rare blood cancer called Waldenström macroglobulinemia (WM). The goal is to see how well this combination can achieve deep, lasting responses by measuring how much cancer remains after treatment. About 43 participants will receive the three-drug combo for four cycles, followed by zanubrutinib alone for eight more months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, China, 300020, China
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.